Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $1.3 billion.

  • Beam Therapeutics' Liabilities and Shareholders Equity rose 1192.74% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 39.68%. This contributed to the annual value of $1.1 billion for FY2024, which is 2438.08% down from last year.
  • Beam Therapeutics' Liabilities and Shareholders Equity amounted to $1.3 billion in Q3 2025, which was up 1192.74% from $1.4 billion recorded in Q2 2025.
  • Beam Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $1.5 billion during Q4 2021, with a 5-year trough of $693.2 million in Q1 2021.
  • For the 5-year period, Beam Therapeutics' Liabilities and Shareholders Equity averaged around $1.3 billion, with its median value being $1.3 billion (2022).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 31561.88% in 2021, then crashed by 2438.08% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Liabilities and Shareholders Equity stood at $1.5 billion in 2021, then dropped by 9.0% to $1.3 billion in 2022, then increased by 8.79% to $1.5 billion in 2023, then dropped by 24.38% to $1.1 billion in 2024, then rose by 18.78% to $1.3 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.